Investors Buy Large Volume of Merck & Co., Inc. Call Options (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) saw unusually large options trading on Friday. Stock traders bought 672,962 call options on the company. This represents an increase of 1,339% compared to the average volume of 46,777 call options.

Merck & Co., Inc. Stock Down 0.3%

MRK opened at $115.61 on Friday. The company has a fifty day moving average price of $115.26 and a 200-day moving average price of $99.68. The firm has a market capitalization of $285.84 billion, a P/E ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRK. UBS Group boosted their price objective on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Citigroup increased their target price on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Royal Bank Of Canada began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.81.

Insider Buying and Selling

In related news, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Caroline Litchfield sold 41,997 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at $10,787,865.12. This represents a 31.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 320,176 shares of company stock worth $38,281,735 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MRK. Chemung Canal Trust Co. increased its stake in Merck & Co., Inc. by 21.1% in the 3rd quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after purchasing an additional 13,285 shares during the period. First Pacific Financial lifted its position in Merck & Co., Inc. by 14.7% in the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after purchasing an additional 6,082 shares during the last quarter. Diversified Trust Co boosted its stake in shares of Merck & Co., Inc. by 9.6% during the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after purchasing an additional 18,187 shares during the period. Caxton Associates LLP boosted its stake in shares of Merck & Co., Inc. by 23.3% during the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after purchasing an additional 7,458 shares during the period. Finally, Thompson Davis & CO. Inc. bought a new position in shares of Merck & Co., Inc. in the second quarter worth approximately $1,168,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.